Abstract
Sudden death as a side effect of action of non-antiarrhythmic drugs is a major pharmacological safety concern facing the pharmaceutical industry and the health regulatory authorities. A number of drugs have been withdrawn from the market in recent years due to cardiovascular toxicity associated with undesirable blockade of hERG potassium channel. Pharmaceuticals of widely varying structure have been shown to interact with hERG. Defining the molecular features that confer hERG inhibitory activity has therefore become a focus of considerable computational and statistical modeling efforts. Some of the approaches are aimed primarily at filtering out potential hERG blockers in the context of virtual libraries, while others involve understanding structure-activity relationships governing hERG-drug interactions. The ability of models to produce structural hypotheses that can be tested by the project teams has become the key prerequisite driving their organization-wide adoption.
Keywords: hERG, QT prolongation, virtual screening, predictive ADMET, pharmacophore
Current Topics in Medicinal Chemistry
Title: Ligand Structural Aspects of hERG Channel Blockade
Volume: 8 Issue: 13
Author(s): Alex M. Aronov
Affiliation:
Keywords: hERG, QT prolongation, virtual screening, predictive ADMET, pharmacophore
Abstract: Sudden death as a side effect of action of non-antiarrhythmic drugs is a major pharmacological safety concern facing the pharmaceutical industry and the health regulatory authorities. A number of drugs have been withdrawn from the market in recent years due to cardiovascular toxicity associated with undesirable blockade of hERG potassium channel. Pharmaceuticals of widely varying structure have been shown to interact with hERG. Defining the molecular features that confer hERG inhibitory activity has therefore become a focus of considerable computational and statistical modeling efforts. Some of the approaches are aimed primarily at filtering out potential hERG blockers in the context of virtual libraries, while others involve understanding structure-activity relationships governing hERG-drug interactions. The ability of models to produce structural hypotheses that can be tested by the project teams has become the key prerequisite driving their organization-wide adoption.
Export Options
About this article
Cite this article as:
Aronov M. Alex, Ligand Structural Aspects of hERG Channel Blockade, Current Topics in Medicinal Chemistry 2008; 8 (13) . https://dx.doi.org/10.2174/156802608785700061
DOI https://dx.doi.org/10.2174/156802608785700061 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Benzopyran Derivatives as Cardio-selective ATP-sensitive Potassium Channel Openers: A Review
Mini-Reviews in Medicinal Chemistry Therapeutic Potential of Endothelial Progenitor Cells for Cardiovascular Diseases
Current Vascular Pharmacology Chemokine Receptors as Targets for Cancer Therapy
Current Pharmaceutical Design Pharmacological Treatment of Vagal Hyperactivity, a Rare but Potentially Fatal Cause of Sudden Cardiac Death
Mini-Reviews in Medicinal Chemistry Drug Discoveries Towards Kv1.5 Potassium Channel
Current Topics in Medicinal Chemistry Remdesivir and Hydroxychloroquine: A Compassionate Use in Covid-19
Current Drug Targets Statins and Cardiovascular Diseases: From Cholesterol Lowering to Pleiotropy
Current Pharmaceutical Design Atrial Macroreentry in Congenital Heart Disease
Current Cardiology Reviews Efficacy and Safety Profile of Aliskiren: Practical Implications for Clinicians
Current Drug Safety Hydrogen Sulphide in Heart and Systemic Circulation
Inflammation & Allergy - Drug Targets (Discontinued) Management of Food-Induced Anaphylaxis: Unsolved Challenges
Current Clinical Pharmacology Immunoadsorption Therapy for Patients with Dilated Cardiomyopathy and Heart Failure
Current Cardiology Reviews Role of Serum and Glucocorticoid-Inducible Kinase (SGK)-1 in Senescence: A Novel Molecular Target Against Age-Related Diseases
Current Medicinal Chemistry Defining Vulnerable Patients with Heart Failure: Opportunistic Lessons from Covid-19
Current Cardiology Reviews Pre-Emptive Conditioning of the Ischemic Heart
Cardiovascular & Hematological Agents in Medicinal Chemistry Functional Properties of Pentacyclic Triterpenes Contained in "Orujo" Olive Oil
Current Nutrition & Food Science Meet the Editorial Board
Current Pharmaceutical Design Recent Advances in Antiarrhythmic Drug Treatment of Atrial Fibrillation
Recent Patents on Cardiovascular Drug Discovery Implantable Cardioverter-Defibrillators in Patients with ESRD: Complications, Management, and Literature Review
Current Cardiology Reviews Are Antipsychotics Useful in the Treatment of Anorexia Nervosa? A Review of the Literature
Current Psychopharmacology